This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Decoding Complexities: Strategies in Diagnosis and Treatment of Migraine

Decoding Complexities: Strategies in Diagnosis and Treatment of Migraine

Format

Webcast

Time to Complete

1 hour

Released

December 20, 2018

Expires

December 20, 2019

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / ABIM Part II MOC Point
1.00 / ABPN Part II MOC Point
1.00 / CNE Contact Hour
1.00 / CE for Nurse Practitioners
1.00 / CE for Pharmacists (0.10 CEUs)

Accredited Provider



This activity is provided by Forefront Collaborative.

Commercial Supporter

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Program Description

Emerging therapies targeting new and diverse mechanisms of disease pathophysiology may be on the cusp of revolutionizing migraine treatment. Join Merle L. Diamond, MD, and Stewart J. Tepper, MD, for this educational program as they detail advances in acute and preventive treatment of migraine and decode complexities of long-term headache management. Real-world cases will be presented from the patient’s point of view describing scenarios encountered in the clinic, with the complicating factors of treatment failures and comorbidities.

Intended Audience

This activity is designed for headache specialists and primary care physicians. Other healthcare professionals who care for patients with headache may also benefit from participation in the educational activity.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Discuss the prevalence and burden of migraine.
  • Develop optimal plans for acute and preventive treatment of migraine, including difficult patients (eg, circumstance of prior treatment failures, contraindications, or comorbidities).
  • Effectively engage patients in the diagnosis of migraine or other primary headache disorders (eg, establishing goals, developing a plan, and considering modifications).
  • Describe newly characterized mechanisms of migraine pathophysiology.
  • Analyze safety/efficacy profiles of new and emerging therapies for acute and preventive migraine treatment.

Fee Information

There is no fee for this educational activity.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Faculty

Merle L. Diamond, MD, has been on an advisory board for Alder BioPharmaceuticals, Allergan, Amgen, Depomed, Eli Lilly and Company, and Supernus Pharmaceuticals; she has been a consultant for Avanir Pharmaceuticals, Eli Lilly and Company, and Pernix Therapeutics and been on a speaker's bureau for Avanir Pharmaceuticals, Depomed, Pernix Therapeutics, and Teva Pharmaceutical Industries. 

Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management, Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.

Accredited Provider Disclosure

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Planner (Forefront Collaborative): Sydney Pate

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Purdue University Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This activity has been approved for 1.00 contact hour.

Credit

1.00

Type

CE for Nurse Practitioners

Accreditation Statement

This activity was planned in accordance with AANP Accreditation Standards and Policies.

Designation Statement

This activity is approved for 1.00 contact hour of continuing education by the American Association of Nurse Practitioners. Activity ID# 18113448.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Designation Statement

Universal Activity Number (UAN): 0018-9999-18-119-H01-P
1.00 contact hour (0.10 CEU).

ABPN MOC Part II Points

The American Board of Psychiatry and Neurology has reviewed Decoding Complexities: Strategies for Diagnosis and Treatment of Migraine and has approved this program as part of a comprehensive program, which is mandated by the ABMS as a necessary component of maintenance of certification.

To Claim this credit type, please fill out the required information in the Evaluation of the activity.

ABIM MOC Part II Point

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



To Claim this credit type, please fill out the required information in the Evaluation of the activity.

Disclosure of Unlabeled Use

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Instructions

During the period December 20, 2018, through December 20, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and evaluation form directly after the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have two opportunities to pass the posttest. To receive credit, you must provide your date of birth and NABP number. All credit information will be uploaded into CPE monitor within 30 days.

If you have any questions relating to the accreditation of this activity, please contact sydney_pate@forefrontcollab.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue